[Wegener's syndrome with renal involvement. Histological, therapeutic and immunopathological study].
D000477:Alkylating Agents / Q000627:therapeutic use; D000936:Antigen-Antibody Complex; D000963:Antimetabolites / Q000627:therapeutic use; D001808:Blood Vessels / Q000276:immunology; D002196:Capillaries / Q000473:pathology; D003165:Complement System Proteins; D005500:Follow-Up Studies; D006101:Granuloma, Giant Cell / Q000209:etiology; D014890:Granulomatosis with Polyangiitis / Q000175:diagnosis / Q000188:drug therapy / Q000276:immunology; D006801:Humans; D006967:Hypersensitivity / Q000175:diagnosis / Q000473:pathology; D007165:Immunosuppression Therapy; D007668:Kidney / Q000276:immunology / Q000473:pathology; D007674:Kidney Diseases / Q000175:diagnosis; D008168:Lung / Q000473:pathology; D008264:Macrophages / Q000276:immunology; D008297:Male; D008833:Microcirculation / Q000473:pathology; D008875:Middle Aged; D013223:Statistics as Topic; D013927:Thrombosis / Q000209:etiology
D000477:Alkylating Agents; D000936:Antigen-Antibody Complex; D000963:Antimetabolites; D003165:Complement System Proteins
Syndrome de Wegener avec atteinte rénale. Considérations histologiques, thérapeutiques et immunopathologiques